Autopsy report · NCT02749071

An Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Reflux

“Met stopping rule per Bayesian analysis”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 5 months before it stopped.
• 161 participants enrolled.
• Results were posted on the registry 6 years 9 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

EndoStim Inc.

Sponsor type

Industry

Conditions

Gastroesophageal Reflux Disease (GERD); Reflux, Gastroesophageal; Gastroesophageal Reflux; Acid Reflux

Interventions

Laparoscopic implantation surgery with or without crural repair; EndoStim stimulation for first six months of study; EndoStim stimulation from Month 6 thru end of study; Sham EndoStim stimulation for first six months of study

Participants

161

Sites

21

Countries

Belgium, Netherlands, United Kingdom, United States

Trials that died the same way

• Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer
  “Closed due to early stopping rule” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.